Valuation : Madrigal Pharmaceuticals, Inc.

Market Cap 12.5B 10.76B 10.12B 9.25B 17.3B 1,180B 17.34B 120B 46.41B 606B 46.94B 45.92B 1,951B P/E 2026 *
-85.7x
P/E 2027 * 86x
Enterprise Value 11.98B 10.31B 9.7B 8.86B 16.57B 1,131B 16.62B 115B 44.46B 580B 44.97B 43.99B 1,869B EV / Sales 2026 *
7.85x
EV / Sales 2027 * 5.39x
Free-Float
94.12%
Yield 2026 *
-
Yield 2027 * -
1 day-0.28%
1 week+1.37%
Current month+0.19%
1 month+6.60%
3 months+9.79%
6 months+24.44%
Current year-7.09%
1 week 523.29
Extreme 523.29
552.08
1 month 494.9
Extreme 494.9
552.08
Current year 416.21
Extreme 416.21
598.79
1 year 393.6
Extreme 393.605
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 9.85
Extreme 9.85
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
17/8/26 Sell

General Counsel

-664 0.0029%
15/8/26 Free

Director

1,725 0.0075%
20/7/26 Sell

Chief Executive Officer

-2,500 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
-0.28%+1.37%+25.48%+192.25% 12.5B
-1.79%-2.27%+50.90%+89.03% 67.98B
-2.06%-0.18%+41.53%+88.17% 64.94B
-0.31%+6.54%-11.39%+457.82% 27.58B
-3.00%-2.90%+39.40%+9.41% 25.74B
+0.86%+1.65%+0.25%-14.78% 26.06B
-1.46%+0.42%+24.07%-18.70% 20.09B
-2.96%-15.21%+210.71%+370.84% 17.16B
-1.49%-4.88%-0.41%+530.26% 14.92B
-0.20%+8.37%+57.87%+159.50% 14.62B
Average -1.27%+0.37%+43.84%+186.38% 29.16B
Weighted average by Cap. -1.47%+0.23%+41.57%+147.10%

Financials

2026 *2027 *
Net sales 1.53B 1.31B 1.24B 1.13B 2.11B 144B 2.12B 14.6B 5.67B 73.94B 5.73B 5.61B 238B 2.14B 1.85B 1.74B 1.59B 2.97B 203B 2.98B 20.52B 7.96B 104B 8.05B 7.88B 335B
Net income -184M -158M -149M -136M -254M -17.36B -255M -1.76B -683M -8.91B -690M -675M -28.69B 200M 172M 162M 148M 277M 18.88B 277M 1.91B 742M 9.69B 751M 735M 31.21B
Net Debt -525M -451M -425M -388M -726M -49.52B -728M -5.02B -1.95B -25.41B -1.97B -1.93B -81.86B -943M -812M -764M -698M -1.3B -89.05B -1.31B -9.02B -3.5B -45.69B -3.54B -3.46B -147B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
04/09/26 US$541.08 -0.28% 177,171
03/09/26 US$542.61 -0.79% 143,455
02/09/26 US$546.93 +1.53% 202,818
01/09/26 US$538.71 -0.24% 165,754
31/08/26 US$540.03 +1.17% 134,578
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
541.08USD
Average target price
678.06USD
Spread / Average Target
+25.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock